Background: Rosuvastatin has been reported to be beneficial in the treatment of dyslipidemia. The C max and AUC 0-t of rosuvastatin were reported to be ~2 to 4 times higher in Chinese subjects compared with white subjects after administration of a single 1-mg/kg dose.
tigators to be mild in intensity, with the exception of 2 cases of abdominal discomfort (1 man and 1 woman, both in the 5-mg dose group). Two women in the 20-mg group experienced dizziness and cold sweats simultaneously. In the 10-mg group, 1 woman had abdominal discomfort and nausea and 1 woman had jaw pain. All reported AEs were considered possibly related to study drug administration.
Conclusions:
In this small study in healthy Chinese volunteers, rosuvastatin systemic exposure appeared to be dose-proportional over the dosing range of 5 to 20 mg with multiple-dose administration. There was no accumulation of rosuvastatin in the body with the 5-and 10-mg doses. However, the results suggest that rosuvastatin might accumulate when the dose is increased to 20 mg. No serious AEs oc- 
INTRODUCTION
Rosuvastatin has been reported to be beneficial in the treatment of dyslipidemia by inhibiting 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity. 1, 2 In clinical trials, rosuvastatin was associated with a reduction in serum LDL-C concentration, a modest increase in serum HDL-C concentration, and a decrease in serum triglyceride concentration. [3] [4] [5] The pharmacokinetics of rosuvastatin have been reported in healthy white volunteers and Chinese subjects. [6] [7] [8] [9] [10] [11] [12] [13] In a trial of the pharmacokinetics of rosuvastatin after single-dose oral administration in Chinese volunteers, AUC and C max were reported to be significantly lower when rosuvastatin 10 mg was administered in the fed versus the fasting state. 10 The C max and AUC 0-t of rosuvastatin 1 mg/kg were found to be ~2 to 4 times higher in Chinese subjects compared with those of white subjects. [10] [11] [12] [13] [14] Despite these findings in Chinese subjects, a search of MEDLINE (2001) (2002) (2003) (2004) (2005) (2006) (2007) ; English and Chinese languages; search terms: rosuvastatin, pharmacokinetics) found no report of the pharmacokinetics and tolerability of multiple-dose administration of rosuvastatin.
The primary end point of this study was to evaluate the pharmacokinetics of multiple doses of rosuvastatin in healthy Chinese volunteers. The secondary end point of the study was to evaluate the tolerability of the drug.
SUBJECTS AND METHODS

Study Protocol and Subjects
The study protocol (2005L03371) was approved by the institutional review board of Sichuan University (Chengdu, China) before the study was conducted in August of 2006. Before entering the study, all subjects provided written informed consent.
Volunteers aged 20 to 25 years with a body mass index of 19 to 25 kg/m 2 who were in good health were eligible for the study. Individuals were excluded if they had clinically significant neoplastic, cardiovascular, hepatic, diabetic, renal, gastrointestinal, metabolic, neurologic, pulmonary, endocrine, or psychiatric disease. Individuals were also excluded from the study if they were taking any drugs, using alcohol or cigarettes (no consumption within a week of enrollment), or had any other characteristic that might confound the interpretation of the results or impair subject response.
Design and Clinical Procedure
This open-label, randomized-sequence, 3-way crossover study was conducted at the West China Second University Hospital (Sichuan, China). The study consisted of three 7-day treatment periods and two 10-day washout periods (Figure 1) . The 10-day washout was chosen as a convenience to the volunteers. Volunteers were randomly allocated using SPSS software version 10.0 (SPSS Inc., Chicago, Illinois) to receive rosuvastatin 5-, 10-, or 20-mg tablets (Jingxin Pharmaceutical Company, Ltd., ( ( Zhejiang, China) daily at 7:00 am under fasting conditions. Breakfast, lunch, and dinner were given to all volunteers at predetermined times. Volunteers were ambulatory during the study but were asked to refrain from strenuous activity. They were under direct medical supervision at the study site for 45 days. Blood samples of ~4 mL were drawn via indwelling catheter (or via syringe when blood clotting occurred) into heparinized tubes (Vacutainer, Becton, Dickinson and Company, Franklin Lakes, New Jersey) before dosing (hour 0) on days 5, 6, and 7, and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, 72 , and 96 hours after the final rosuvastatin dose was administered on day 7. The blood samples were centrifuged at 1500g for g 10 minutes at room temperature. Plasma was separated and kept frozen at -80°C in coded polypropylene tubes. Samples were analyzed at the Department of Clinical Pharmacy and Pharmaceutical Administration, School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
Materials
Estrone (purity 98%), which was used as the internal standard, was obtained from the Chinese National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Methanol, glacial acetic acid, and formic acid were purchased from Tedia Co., Inc. (Fairfield, Iowa) and tetrabutyl ammonium hydroxide (TAH) was purchased from Kalong Chemical (Chengdu, China). Ethyl acetate was obtained from Ark Chemical (Chengdu, China). Water was obtained by distillation in glass and passage through a water purification system (Milli-Q Plus, Millipore, Bedford, Massachusetts). Methanol, glacial acetic acid, and water were the appropriate grades for use in HPLC. Ethyl acetate was analytically pure and redistilled; the other reagents were analytically pure.
Tolerability Assessments
Adverse events (AEs) were monitored throughout the study via subject interview, vital signs, and laboratory measurements. Rescue medications and first aid drugs were available at the experiment site to ensure the volunteers' safety. Physicians and nurses were present during the trial and judged which symptoms were study-drug related. The laboratory profile, which included a clinical chemistry profile (creatinine, total bilirubin, direct bilirubin, alanine aminotransferase [ALT], aspartate aminotransferase, alkaline phosphatase, creatine kinase [CK]) and urinalysis (specific gravity, pH, protein, and plasma), was assessed before and after the study. A 12-lead ECG was obtained at the beginning and completion of the study. Vital signs (body temperature, blood pressure, and heart rate) were measured daily until the fifth day, after which blood was drawn daily. Axillary body temperature was measured using a thermometer (Diling Thermometer Company, Ltd., Jiangsu, China); blood pressure and heart rate were measured electronically using a vital-signs monitor (Panasonic Corporation of China, Beijing, China). Serious AEs were those requiring hospitalization, treatment discontinuation, or resulting in death.
Analysis of Samples
Preparation of Standard and Quality Control Samples
According to the method of Lan et al, 15 the standard curve of rosuvastatin in human plasma is 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, and 100 ng/mL. The concentration of internal standard in plasma was 100 ng/mL. Quality control (QC) samples were prepared on the day of analysis and in bulk at 4 concentrations: 0.1, 0.5, 10, and 50 ng/mL. The internal standard stock solution was made up in methanol at a concentration of ~50 μg/mL and was stored at -20°C and protected from light for ≤1 month. On the day of analysis, a dilution of this solution was prepared in methanol to a concentration of ~1000 ng/mL.
Sample Treatment
Control (blank) plasma was obtained from the Chengdu Blood Center (Chengdu, China) for calibration, and bulk spiked QC samples were removed from the freezer and allowed to thaw to room temperature (~4 hours) before extraction. Control plasma with a volume of 1100 μL (1.0 mL of blank plasma spiked with 100 μL of working standard solutions of various concentrations) and sample plasma with a volume of 1100 μL (1.0 mL of sample plasma added to 100 μL of 1 M acetic acid/methanol [50:50 v/v]) were prepared for extraction. Then, 100 μL of 0.5% acetic acid in water and 600 μL of 0.5% TAH in water were added to form an ion pair with rosuvastatin; subsequently, 100 μL of internal standard working solution was added. A sample was extracted using 4 mL of ethyl acetate in a vortex shaker (Vortex Genius 3, IKA-Werke GmbH & Co., Staufen, Germany). The upper organic phase was transferred and evaporated to dryness under a stream of nitrogen at 40°C (N-EVAP 11155, Organomation Associates, Inc., Berlin, Massachusetts). The residue was reconstituted in 200 μL of 0.5% acetic acid in water/methanol (50:50 v/v). The sample was transferred to the glass autosampler vial insert and 50 μL was injected into the chromatographic system.
Chromatography and Mass Spectrometry
We used the same methods for analyzing rosuvastatin as those of Lan et al, 15 as conducted in our previous single-dose analysis of rosuvastatin. 10 
Pharmacokinetic and Statistical Analysis
The steady-state C max (C ssmax ) and T max were observed visually from the plots of rosuvastatin plasma concentration versus time. All data were processed using DAS software version 2.0 (Drug and Statistics, Anhui, China) to construct pharmacokinetic profiles. Accumulation factor is the ratio of the steady-state concentration to the concen r -tration after the first administration.
The primary data analysis included all study participants, and tolerability data were summarized descriptively. The Newman-Keuls test was used to evaluate the differences in AUC 0-t /dose, C ssmax /dose, and t 1/2 among the 3 doses administered. The statistical significance of t 1/2 , C ssmax , and AUC 0-t between the male and female groups and the 2 forms of administration (single-and multiple-dose) was evaluated using the t test. The Wilcoxon t rank sum test was used to analyze the differences in T max . P < 0.05 was considered statistically significant. A sample size calculation was not performed.
RESULT L L S
Eighteen individuals were approached to enroll in the study, but 6 were excluded because they were currently administering drugs (n = 2) or they were smoking cigarettes (n = 4). Twelve healthy Chinese volunteers (6 (Table I) .
Pharmacokinetics
The mean C ssmax and AUC 0-t values were both linear in the range of doses administered. The mean (SD) C ssmax was significantly greater after rosuvastatin administration in the 20-mg group compared with the 5-mg group (37.69 [29.83] vs 6.17 [6. 03] ng/mL; P = 0.04) (Figure 2 Table II) . The accumulation factor was 1.07 (0.22), 1.00 (0), and 3.13 (4.79) in the rosuvastatin 5-, 10-, and 20-mg groups, respectively (Table II) .
C ssmax , T max , t 1/2 , and AUC 0-t were compared between the male and female subjects. For the 5-mg dose, C ssmax was significantly higher in the women compared with the men (7.29 [3.67] (Table III) .
Tolerability
No serious AEs occurred during the study. All AEs were considered by the investigators to be mild in intensity, with the exception of 2 cases of moderate abdominal discomfort (1 man and 1 woman, both with the 5-mg dose). Two women in the 20-mg group experienced dizziness and cold sweats simultaneously, and were treated successfully with oral glucose. In the 10-mg group, 1 woman had abdominal discomfort and nausea that resolved without treatment and one had jaw pain that resolved after a 3-day regimen of amoxicillin 0.25 g TID ( Table IV) . The possibility of BMI = body mass index. *P < 0.001 versus males. P acupuncture syncope could not be eliminated because blood samples were drawn via syringe instead of via the indwelling catheter in subjects who experienced blood clotting. All reported AEs were considered possibly related to study drug administration. Three subjects had an increased white blood cell count and serum CK and ALT levels ≥2 times the upper limit of normal on day 7 ( Table V) ; none of the increases was considered clinically significant. Two and 3 subjects, respectively, had ALT and CK >1 times upper limit of normal. One subject had simultaneous increases in ALT, direct bilirubin, and CK. Another subject had simultaneous increases in total bilirubin, direct bilirubin, and CK. All subjects who had increased laboratory values recovered without additional treatment.
DISCUSSION
The statistical differences in t 1/2 between rosuvastatin 20 mg and the other doses were consistent with nonlinear dynamics. The long t 1/2 and the large accumulation factor with the 20-mg dose may have contributed to the saturation of some enzymes. The rosuvastatin absorption rate was considerably slower than its elimination rate, indicating that the drug may exhibit absorption rate-limited elimination (flip-flop ( pharmacokinetics). The lower first-order absorption rate constant was re- No statistically significant differences were found in the T max , AUC 0-t , and C max between single-and multiple-dose administration. 10 With rosuvastatin 5 mg, the t 1/2 with single-dose administration was significantly longer than that with multiple-dose administration. Sex had no influence on rosuvastatin pharmacokinetics in the single-dose study; however, in the multiple-dose study, significant differences in the rate and degree of absorption were found between male and female subjects. These findings suggest that sex has an influence after prolonged administration.
According to the pretesting, the steady-state concentration was achieved after 4 days of administration. The concentration was less than one twentieth of C ssmax and most of the increased laboratory findings occurred 96 hours after the end of the 7-day drug administration period. Blood samples were collected beginning on day 5, and all laboratory values were monitored for 96 hours after the treatment period.
This study had several limitations. The small study population, open-label design, dosages used, use of only Chinese subjects, and duration of observation make it difficult to generalize these results to a larger population. Furthermore, the results may be different in patients compared with healthy volunteers. Relatively large SDs were found in the pharmacokinetic parameters. 
CONCLUSIONS
In this small study in healthy Chinese volunteers, rosuvastatin systemic exposure appeared to be dose-proportional over the dosing range of 5 to 20 mg with multipledose administration. There was no accumulation of rosuvastatin in the body with the 5-and 10-mg doses. However, the results suggest that rosuvastatin may have accumulated when the dose was increased to 20 mg. No serious AEs or deaths occurred with any of the 3 doses studied.
